Judgment — ECLI:EU:C:2016:136
Date: 2016-03-03
Language of the case: English
Court formation: Sixth Chamber
Subject matter: Approximation of laws;Public health
Procedure: Action for annulment;Appeal - unfounded
Origin: Netherlands

Judgment of the Court (Sixth Chamber) of 3 March 2016 — Teva Pharma BV, Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA), European Commission (Case C-138/15 P) 1 (Appeal — Orphan medicinal products — Regulation (EC) No 141/2000 — Regulation (EC) No 847/2000 — Refusal to grant marketing authorisation for the generic version of the orphan medicinal product ‘imatinib mesylate’) Language of the case: English Parties Appellants: Teva Pharma BV, Teva Pharmaceuticals Europe BV (represented by: K. Bacon QC, E. Mackenzie, Barrister, and G. Morgan, Solicitor) Other parties to the proceedings: European Medicines Agency (EMA) (represented by: N. Rampal Olmedo, M. Tovar Gomis, S. Marino and T. Jabłoński, acting as Agents), European Commission (represented by: A. Sipos and M. Šimerdová, acting as Agents) Operative part of the judgment The Court: Dismisses the appeal. Orders Teva Pharma BV and Teva Pharmaceuticals Europe BV to bear their own costs and to pay the costs incurred by the European Medicines Agency (EMA). Orders the European Commission to bear its own costs. ____________ 1 OJ C 190, 8.6.2015.